Bioverativ, A Sanofi Company

This early-stage study tested a single injection of an experimental drug called BIVV001 in six adults with severe forms of von Willebrand disease (VWD), a bleeding disorder. The main goals were to see how long the drug stays active in the body and to check for any safety issues. …

This early-stage study tested the safety and effects of a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare autoimmune condition where the immune system attacks red blood cells. The main goal was to see if the drug was safe and t…

This study tested a new, long-acting version of the missing clotting factor (called BIVV001) in children under 12 with severe hemophilia A. The main goal was to see if it was safe and effective at preventing and treating bleeding episodes over a year. The study involved 74 childr…

This study tested a new long-acting treatment called BIVV001 for people with severe Hemophilia A, a condition where blood doesn't clot properly. The goal was to see if a single weekly injection could safely prevent bleeding episodes and treat bleeds when they happen. The trial in…

This study tested an experimental drug called BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The main goal was to see if BIVV020 could safely help increase and maintain platelet counts over a l…

This study tested an experimental drug called SAR445088 in adults with CIDP, a rare condition that causes progressive weakness and numbness. The main goal was to see if the drug could control the disease and prevent relapses in different groups of patients, including those who do…